ReviewJournal of clinical medicine2020
Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series.Frontiers in neurology · 2024Pooled it
- Pooled it
- Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System.Frontiers in allergy · 2022Pooled it
- Article
- Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.Cancer chemotherapy and pharmacology · 2026Review
- Article
- Growth Differentiation Factor-15 Could Predict Decreased Hemoglobin in Tuberculosis Treated With Linezolid-Containing Regimen.The clinical respiratory journal · 2026Article
- Severe Postoperative Epistaxis Revealing Immune Thrombocytopenia: A Case Report.Journal of rhinology : official journal of the Korean Rhinologic Society · 2026Article
- From Epistaxis to a Platelet Count of Four: A Rare Presentation of Teicoplanin-Induced Thrombocytopenia.Cureus · 2026Article
- The evolving landscape of platelet therapy: risks, innovations, and clinical judgment.Annals of hematology · 2026Review
- Case report: Butylphthalide-associated severe thrombocytopenia, a rare adverse drug reaction.Frontiers in pharmacology · 2026Article
- Thrombocytopenia and anemia associated with piperacillin-tazobactam: integrating clinical case series with FAERS disproportionality analysis.Frontiers in pharmacology · 2026Article
- Minor trauma-induced eccrine porocarcinoma of the toe in a patient on long-term carbamazepine: a case report and literature review.Frontiers in oncology · 2026Article
- Piperacillin-tazobactam-associated thrombocytopenia with negative antiplatelet antibody testing: a case report and literature review.Frontiers in medicine · 2026Article
- Successful Treatment of Oxaliplatin-Induced Immune Thrombocytopenia in a Schizophrenic Patient With Contraindication to Steroids Using Cyclosporine Plus Eltrombopag: A Case Report.Case reports in medicine · 2026Article
- Severe thrombocytopenia following exposure to orlistat, alkylphenol, and pyrethroids: coincidence or causation?Revista peruana de medicina experimental y salud publica · 2025Article
- Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort.Blood advances · 2025Article
- Unexpected thrombocytopenia of a rare tamoxifen-induced complication in breast cancer therapy: A case report.World journal of clinical cases · 2025Article
- Article
- A Case of Piperacillin-Induced Immune Thrombocytopenia: Diagnostic Challenges and Management.Cureus · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced immune thrombocytopenia (DITP) is a life-threatening clinical syndrome that is under-recognized and difficult to diagnose. Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin. Several different mechanisms have been identified in typical DITP, which is most commonly characterized by severe thrombocytopenia due to clearance and/or destruction of platelets sensitized by a drug-dependent antibody. Patients with typical DITP usually bleed when symptomatic, and biological confirmation of the diagnosis is often difficult because detection of drug-dependent antibodies (DDabs) in the patient's serum or plasma is frequently not possible. This is in contrast to heparin-induced thrombocytopenia (HIT), which is a particular DITP caused in most cases by heparin-dependent antibodies specific for platelet factor 4, which can strongly activate platelets in vitro and in vivo, explaining why affected patients usually have thrombotic complications but do not bleed. In addition, laboratory tests are readily available to diagnose HIT, unlike the methods used to detect DDabs associated with other DITP that are mostly reserved for laboratories specialized in platelet immunology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.